A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Not Applicable
Recruiting
- Conditions
- Prostatic Cancer, Castration-Resistant
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT07047118
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
Not Applicable
Recruiting
- Conditions
- Difficult-to-treat Rheumatoid Arthritis (RA) and Severe, Refractory Sjögren's Disease (SjD)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT07048197
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Exploratory Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Phase 2
Not yet recruiting
- Conditions
- Primary Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT07039422
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT07039383
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
Not yet recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT07036718
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Phase 4
Not yet recruiting
- Conditions
- Atherosclerotic Cardiovascular Disease
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 326
- Registration Number
- NCT07034690
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.
Phase 1
Not yet recruiting
- Conditions
- Autoimmune and Chronic Inflammatory Diseases
- Interventions
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT07032272
Home Reported Outcomes in C3G Study
Recruiting
- Conditions
- C3 Glomerulopathy
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT07029542
- Locations
- 🇺🇸
Novartis Investigative Site, East hanover, New Jersey, United States
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT07029555
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
Completed
- Conditions
- Food HypersensitivityAnaphylaxis
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT07027163
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States